Key takeaways

  • Recce Pharmaceuticals (ASX: RCE) received about A$3.67 million from the ATO, comprising roughly A$3.57 million in overseas R&D expenditure and A$95,826 in ATO interest, relating to the year ended 30 June 2025.
  • The refund lifts the company's pro-forma cash position to approximately A$33.1 million, up from a previously stated figure near A$29.5 million.
  • The inflow follows a recently completed A$4 million institutional placement priced at A$0.40 per share and a Share Purchase Plan opened to eligible shareholders.
  • Management has flagged an additional R&D Tax Incentive rebate of around A$7.5 million anticipated for the financial year ending 30 June 2026.
  • Shares in the company were trading up 2.86% at A$0.36 on 23 July 2026.

Recce Pharmaceuticals Limited (ASX:RCE) told the market it had received a A$3.7 million refund from the Australian Taxation Office — comprising roughly A$3.57 million in overseas R&D expenditure and A$95,826 in ATO interest for the year ended 30 June 2025 — lifting the clinical-stage biotechnology company's pro-forma cash position to approximately A$33.1 million. Shares traded up 2.86% to A$0.36 on 23 July 2026 as investors welcomed the non-dilutive cash inflow, which extends Recce's operational runway as it advances dual Phase 3 programs for RECCE 327: one targeting diabetic foot infections and a second targeting septicaemia. With a further tax refund of around A$7.5 million anticipated for the year ending 30 June 2026, the company's near-term funding position looks more secure than balance-sheet cash alone might suggest.

What Recce announced

Recce Pharmaceuticals disclosed that it had banked a cash refund of approximately A$3.67 million from the ATO. According to the company's disclosure, the payment is made up of about A$3.57 million relating to overseas research and development expenditure and a further A$95,826 in interest paid by the ATO. The amount is connected to the financial year ended 30 June 2025.

The practical effect highlighted by the company is a stronger cash position. Recce said the refund lifts its pro-forma cash to approximately A$33.1 million, compared with a figure closer to A$29.5 million referenced previously. For a pre-revenue, clinical-stage business, non-dilutive cash of this kind is notable because it supplements funding raised from investors without issuing new shares to obtain it.

The R&D Tax Incentive is an Australian Government program that provides eligible companies with a refundable offset for qualifying research and development activity. Because much of Recce's spend supports its clinical pipeline, the program is a recurring source of cash for the business. Management indicated it anticipates an additional R&D Tax Incentive rebate of around A$7.5 million for the financial year ending 30 June 2026, although any such future rebate would be subject to the usual eligibility assessment and timing considerations and should not be treated as certain.

Balance sheet and recent capital activity

The ATO refund arrives alongside recent capital-markets activity. Recce recently completed an A$4 million institutional placement, issuing 10 million shares at A$0.40 each. The company also opened a Share Purchase Plan (SPP) to eligible shareholders, which was structured to target up to a further A$4 million, taking the combined potential raise to as much as A$8 million.

Recce has outlined how it intends to deploy its capital. Based on the company's disclosures, the intended allocation includes approximately A$3.2 million toward commercial licensing discussions with a Middle Eastern pharmaceutical company, around A$2 million toward Phase 3 diabetic foot infection trial activity in Indonesia and Australia, roughly A$2 million toward regulatory applications with the US Food and Drug Administration (FDA) and Indonesia's BPOM authority, and about A$800,000 for general working capital and offer costs.

In its most recent quarterly disclosures, the company reported net operating cash outflows of around A$2.2 million for the June 2026 quarter, a reminder that, like most clinical-stage biotechnology companies, Recce continues to consume cash as it funds trials and regulatory work ahead of any potential commercial revenue.

The clinical and commercial backdrop

Recce Pharmaceuticals is developing a class of synthetic anti-infectives, with its lead asset the RECCE® 327 Topical Gel (R327G). The company's headline clinical effort is in diabetic foot infections, a serious and often difficult-to-treat complication of diabetes, where it is pursuing a dual Phase 3 strategy across two geographies.

In Australia, the program has been cleared to advance from Phase 2 to pivotal Phase 3 status. The company has described enrolling up to 200 patients with expanded eligibility that includes moderate infections, with an interim analysis planned after half of the enrolled patients complete treatment and full recruitment anticipated by the end of 2027. In Indonesia, Recce has said patient dosing is underway, with an interim data readout expected after 155 of a planned 310 patients have been enrolled. The company has also noted that its Indonesian trial site completed a regulatory inspection.

Beyond the diabetic foot infection work, Recce has previously pointed to activity connected to a United States burn wound program. On the commercial side, the company has signed a non-binding term sheet with a Middle Eastern pharmaceutical partner covering markets including Saudi Arabia, other Gulf Cooperation Council nations, Egypt, Algeria and Morocco. The company has described potential terms including an upfront fee and milestone payments totalling up to US$3.5 million plus royalties on net sales. Because that arrangement is non-binding, it may change or may not convert into a definitive agreement.

Management framed the funding and pipeline progress positively. Chief Executive Officer James Graham said the capital raising came at what he described as an exciting time for the company, referencing upcoming interim data in Indonesia as a step toward the potential commercialisation of R327G.

Potential opportunities and positive factors

Several elements of the update may be viewed constructively. The most immediate is the non-dilutive nature of the ATO refund: unlike an equity raise, the R&D refund adds cash without issuing new shares, and the flagged prospect of a larger rebate for the 2026 financial year points to a repeatable funding mechanism tied to ongoing R&D activity.

The strengthened pro-forma cash balance of about A$33 million also gives the company greater latitude to fund its Phase 3 programs and regulatory submissions. For a company operating in the capital-intensive drug-development sector, a clearer near-term funding runway can reduce the pressure to raise equity in less favourable conditions. In addition, the dual-geography Phase 3 approach and the potential Middle East licensing arrangement offer multiple pathways through which the company hopes to generate value, should trials and negotiations progress as intended.

Material risks, uncertainties and investor considerations

The positives sit alongside meaningful risks. Recce remains a pre-revenue, clinical-stage company that continues to burn cash, as its reported June-quarter operating outflow illustrates. Drug development is inherently uncertain: Phase 3 trials can fail to meet endpoints, timelines can slip, and regulatory approvals from bodies such as the FDA and BPOM are never guaranteed.

What investors may watch next

Key milestones investors may monitor include the interim data readout from the Indonesian Phase 3 diabetic foot infection trial once the relevant enrolment threshold is reached, progress and recruitment updates from the Australian Phase 3 program, and the outcome of regulatory applications with the FDA and BPOM. Market watchers may also look for confirmation of the additional R&D Tax Incentive rebate for FY2026, the outcome of the SPP, and whether the non-binding Middle East term sheet advances to a binding agreement. Ongoing quarterly cash-flow reports will remain relevant for assessing the company's funding runway.